AMA submission to the Therapeutic Goods Administration - proposed amendments to the Poisons Standard – June 2020

In this submission, the AMA provides feedback to the medicine scheduling proposals for June 2020. The AMA does not oppose the proposed changes to oxymetazoline, clotrimazole, cumyl-pegaclone, nicotine, methylisothiazolinone and methylchloroisothiazolinone, and isothiazolinones. The AMA supports increased access to eletriptan. The AMA opposes the proposed changes to sildenafil, ibuprofen, and cannabidiol.